Investor Information

News

Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab

View News

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

View News

More Information

Share Price

NASDAQ: SMMT

11.55 USD

26-Jul-2024 16:00 UTC-4

More Information

SEC Filings

Current report filing

View News

Statement of changes in beneficial ownership of securities

View News

More Information

Email Alerts